Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Facet and Trubion collaborate on TRU016 for CLL; deal ends

Executive Summary

Cancer drug companies Facet Biotech (spun off from PDL BioPharma in 2008) and Trubion Pharmaceuticals have signed an exclusive joint development and worldwide commercialization agreement for Trubion's chronic lymphocytic leukemia candidate TRU016, which is in Phase I clinical trials.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information

Related Companies